BioAtla
BCAB
97 hedge funds and large institutions have $128M invested in BioAtla in 2022 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 32 increasing their positions, 19 reducing their positions, and 12 closing their positions.
150% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 12
68% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 19
37% more call options, than puts
Call options by funds: $596K | Put options by funds: $436K
23% more funds holding
Funds holding: 79 → 97 (+18)
0.07% less ownership
Funds ownership: 1.49% → 1.43% (-0.07%)
75% less capital invested
Capital invested by funds: $518M → $128M (-$391M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$7.81M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$6.9M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$6.71M |
| 4 |
Renaissance Technologies
New York
|
+$3.89M |
| 5 |
Two Sigma Investments
New York
|
+$3.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$19.4M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$17M |
| 3 |
PA
Perceptive Advisors
New York
|
-$13M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$8.76M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.38M |
BCAB Hedge Fund Activity: Q1 2022 in Review
97 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in BioAtla (BCAB) for Q1 2022, worth a combined $128M — down 75% from $518M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new BCAB positions and 12 closed out — a net gain of 18 holders — while 32 added to existing stakes and 19 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $7.81M. The largest seller was Wellington Management Group, cutting an estimated $19.4M.
- 97 institutional investors held BioAtla (BCAB) as of Q1 2022, up from 79 in Q4 2021.
- Funds reported $128M of BioAtla stock for Q1 2022, down 75% quarter-over-quarter.
- 30 funds opened new BioAtla positions in Q1 2022 and 12 closed out, a net change of +18 holders.
- The largest BioAtla buyer in Q1 2022 was Morgan Stanley, an estimated $7.81M added.
- The largest BioAtla seller in Q1 2022 was Wellington Management Group, an estimated $19.4M sold.
Based on aggregated 13F filings for Q1 2022.